Highlights From the 2016 ASCO Cancer Survivorship Symposium

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Benjamin J. Golas, MD

OST-HER2 Shows Significant EFS Improvement in Metastatic Lung Osteosarcoma

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

A total of 35% of patients with fully resected metastatic lung osteosarcoma treated with OST-HER2 achieved a 1-year event-free survival.

Roman Fabbricatore

Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting

A total of 35% of patients with fully resected metastatic lung osteosarcoma treated with OST-HER2 achieved 1-year event-free survival.

Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Stephen V. Liu, MD;Joshua K. Sabari, MD

June 23rd 2025

3 Things You Should Know About Advancing mCRPC Care: Targeted Sequencing, Epigenetics, and Emerging Strategies

Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Discover the latest advancements in metastatic castration-resistant prostate cancer care, including personalized treatment strategies and emerging therapies.

ONCOLOGY Staff

High Tumor Volume Confers CAR T-Cell Therapy Toxicity Risk in LBCL

Discover the latest advancements in metastatic castration-resistant prostate cancer care, including personalized treatment strategies and emerging therapies.

Data support incorporating volumetric PET biomarkers into toxicity risk prediction for patients receiving CAR T-cell therapy for LBCL.

Russ Conroy

17 Salmonella and the Breast: A Literature Review of Salmonella-Induced Breast Abscesses

Data support incorporating volumetric PET biomarkers into toxicity risk prediction for patients receiving CAR T-cell therapy for LBCL.

Related Content

Daniella Natanov;Sharon Koehler

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

Benjamin J. Golas, MD

OST-HER2 Shows Significant EFS Improvement in Metastatic Lung Osteosarcoma

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Roman Fabbricatore

Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting

A total of 35% of patients with fully resected metastatic lung osteosarcoma treated with OST-HER2 achieved 1-year event-free survival.

Stephen V. Liu, MD;Joshua K. Sabari, MD

June 23rd 2025

3 Things You Should Know About Advancing mCRPC Care: Targeted Sequencing, Epigenetics, and Emerging Strategies

Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

ONCOLOGY Staff

High Tumor Volume Confers CAR T-Cell Therapy Toxicity Risk in LBCL

Discover the latest advancements in metastatic castration-resistant prostate cancer care, including personalized treatment strategies and emerging therapies.

Russ Conroy